Autism and Mesenchymal Stem Cells

Autism Spectrum Disorder (ASD) is a multifactorial neurodevelopmental condition. ASD is characterized by impairments in social communication and repetitive behaviors. Increasing recognition of neurogenetic, immune, and metabolic underpinnings have spurned a plethora of therapeutic strategies. Despite advances in early behavioral interventions and symptomatic pharmacotherapy, no disease-modifying treatments exist. Stem cell therapy has emerged as an experimental approach, targeting the physiological and neurobiological constructs of ASD through mechanisms such as immunomodulation, neuroprotection, and metabolic support. The potent anti-inflammatory and neurotrophic effects of mesenchymal stem cells (MSCs) provide a novel strategy to address the pathophysiological underpinnings. MSCs have demonstrated safety and early efficacy in preclinical models and small clinical studies. Hematopoietic stem cells (HSCs) have also been investigated, particularly in subtypes of ASD associated with immune dysfunction. Preliminary trials suggest that both autologous and allogeneic stem cell infusions may improve core and associated ASD symptoms, though findings remain equivocal due to heterogeneity in patient populations, treatment protocols, and outcome measures. Meta- analyses suggest potential clinical benefit and minimal serious adverse events; however, the evidence base is limited by small sample sizes, short follow-up, and lack of standardized biomarkers or patient stratification strategies. Age, body size, and inflammatory status may also influence response, underscoring the need for personalized approaches. This review synthesizes the current preclinical and clinical literature on stem cell therapies in ASD, with emphasis on mechanistic rationale, treatment heterogeneity, and future directions for research. Larger, controlled trials are needed to clarify optimal stem cell sources, dosing regimens, and responder phenotypes, and to determine whether stem cell-based interventions can achieve durable functional improvements in ASD.

Publication Details

Journal
Neurology - Research & Surgery
Published
2025-09-26
DOI
https://doi.org/10.33425/2641-4333.1081
Primary Topic
Market Dynamics and Volatility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Autism and Mesenchymal Stem Cells

Neurology - Research & Surgery
Market Dynamics and Volatility
article

Autism and Mesenchymal Stem Cells

article en

Abstract

Autism Spectrum Disorder (ASD) is a multifactorial neurodevelopmental condition. ASD is characterized by impairments in social communication and repetitive behaviors. Increasing recognition of neurogenetic, immune, and metabolic underpinnings have spurned a plethora of therapeutic strategies. Despite advances in early behavioral interventions and symptomatic pharmacotherapy, no disease-modifying treatments exist. Stem cell therapy has emerged as an experimental approach, targeting the physiological and neurobiological constructs of ASD through mechanisms such as immunomodulation, neuroprotection, and metabolic support. The potent anti-inflammatory and neurotrophic effects of mesenchymal stem cells (MSCs) provide a novel strategy to address the pathophysiological underpinnings. MSCs have demonstrated safety and early efficacy in preclinical models and small clinical studies. Hematopoietic stem cells (HSCs) have also been investigated, particularly in subtypes of ASD associated with immune dysfunction. Preliminary trials suggest that both autologous and allogeneic stem cell infusions may improve core and associated ASD symptoms, though findings remain equivocal due to heterogeneity in patient populations, treatment protocols, and outcome measures. Meta- analyses suggest potential clinical benefit and minimal serious adverse events; however, the evidence base is limited by small sample sizes, short follow-up, and lack of standardized biomarkers or patient stratification strategies. Age, body size, and inflammatory status may also influence response, underscoring the need for personalized approaches. This review synthesizes the current preclinical and clinical literature on stem cell therapies in ASD, with emphasis on mechanistic rationale, treatment heterogeneity, and future directions for research. Larger, controlled trials are needed to clarify optimal stem cell sources, dosing regimens, and responder phenotypes, and to determine whether stem cell-based interventions can achieve durable functional improvements in ASD.

Neurology - Research & SurgeryVol. 8(3)
Openalex Percentile: Top 35%
Market Dynamics and Volatility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.